Form 4: Recursion Pharmaceuticals CFO Michael Secora Reports Tax-Related Stock Disposal

Sentiment:

SEC Form 4 Filing


Michael Secora, CFO of Recursion Pharmaceuticals, reports the disposal of 11,962 shares to cover tax obligations related to restricted stock units.

Summary

  • On August 15, 2024, Michael Secora, the Chief Financial Officer of Recursion Pharmaceuticals, reported a transaction involving Class A Common Stock.
  • Secora disposed of 11,962 shares to satisfy tax withholding obligations related to the net settlement of restricted stock units.
  • The shares were disposed of at a price of $6.69 per share.
  • Following the transaction, Secora beneficially owns 1,353,381 shares of Class A Common Stock directly.
  • Secora also holds multiple stock options with varying exercise prices and expiration dates.

Sentiment

Score: 5

Explanation: This is a neutral event. It's a routine transaction related to tax obligations and doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. This filing indicates activity by the CFO, which is always relevant for investors to monitor.

Key Dates

DateDescription
02/04/2022Stock Option (Right to Buy) $ 11.4
03/01/2023The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
03/01/2024The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
08/15/2024Date of transaction: disposal of 11,962 shares of Class A Common Stock.
08/19/2024Date of signature for the Form 4 filing.
02/04/2032Stock Option (Right to Buy) $ 11.4
02/01/2033Stock Option (Right to Buy) $ 8.55
02/09/2034Stock Option (Right to Buy) $ 10.09

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.